Company: PFSA
Filing Date: 2025-04-28
Form Type: S-4/A
Source: 0001213900-25-035718
Chunk: 75

Company: Profusa, Inc.
Filing Date: 2025-04-28
Form: S-4/A
Chunk 75
---
 PIPE Subscription Agreement, the PIPE Investors are expected, subject to the conditions relating to such purchase set forth in the PIPE Subscription Agreement, to purchase from NorthView senior secured convertible notes in an aggregate principal amount of up to $22,222,222 (the “PIPE Convertible Notes”) for a purchase price of up to $20,000,000, after 10% OID. The PIPE Subscription Agreement contemplates that the PIPE Convertible Notes will be purchased (the “Investment” or the “PIPE”) across multiple tranches. The proceeds from the purchase of the PIPE Convertible Notes will be used for working capital purposes. The potential dilutive impact of the PIPE Subscription Agreement is described further in the section of this proxy statement/prospectus entitled “Questions And Answers About The Proposals — How will the level of redemptions by NorthView’s stockholders affect the ownership of non -redeeming NorthView’s stockholders in New Profusa upon the closing of the Business Combination?” Reasons for the Approval of the Business Combination After careful consideration, NorthView’s Board recommends that NorthView Holders vote “FOR” each proposal being submitted to a vote of the NorthView Holders at the special meeting. In considering its recommendation to its stockholders, the board has identified certain factors in making the determination, including but not limited to: •Profusa is in the health care sector with near term revenue potential. Its biosensor technology and developed applications have been validated and its Lumee O2 product is approved in EU while seeking FDA approval in US; •Profusa’s biosensor technology and AI monitoring is a true platform with meaningful revenue growth prospects; •Profusa’s proven and experienced management team led by Ben Hwang, PhD and co -founder; and •The Marshall and Stevens fairness opinion (See “ The Business Combination Proposal— Opinion of Marshall & Stevens” for additional information regarding the preparation of the fairness opinion). For a description of NorthView’s reasons for the approval of the Business Combination and the recommendation of NorthView’s Board, see the section entitled “ The Business Combination — The NorthView Board’s Reasons for the Approval of the Business Combination”. Redemption Rights Pursuant to NorthView’s Amended and Restated Certificate of Incorporation, we are providing our public stockholders with the opportunity to redeem all or a portion of their public shares of NorthView Common Stock for cash upon consummation of the Business Combination. The per share redemption price will be equal to the aggregate amount then on deposit in the Trust Account that holds the proceeds of